Physician profile
Amy E Rousseau
NPI 1962023630
$3,009.59
in general payments reported to CMS, 2019-2025
26 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.19 · 2022: $109 · 2023: $473 · 2024: $1,243 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,826.61 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $457.35 | 2021-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $438.62 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $385.32 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $273.29 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $267.70 | 2023-2025 | |
| Glaxosmithkline, LLC. | $263.79 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $199.14 | 2023-2025 | Zepbound, Mounjaro, Emgality |
| Astellas Pharma US INC | $84.78 | 2023-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $81.70 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Exact Sciences Corporation | $74.55 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $52.95 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.73 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $51.54 | 2024-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Axsome Therapeutics, INC. | $49.95 | 2025 | Auvelity |
| Lundbeck LLC | $37.54 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.86 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.94 | 2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $24.83 | 2024 | |
| Dexcom, INC. | $23.79 | 2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $23.58 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $22.10 | 2023 | Eliquis |
| Sumitomo Pharma America, INC. | $21.07 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $18.55 | 2022 | |
| Medtronic, INC. | $17.29 | 2025 | Minimed 780g |
| Aimmune Therapeutics, INC. | $15.41 | 2025 | Vowst |
| Alkermes, INC. | $15.22 | 2025 | Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Rousseau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.